Pharmacokinetics of HCFC-123 in Dogs.
Abstract
The U.S. EPA has been mandated to evaluate alternatives to Class I ozone depleting substances including halon fire and explosion protection agents. Under the Significant New Alternatives Policy Program the EPA considers the cardiac sensitization potential as the most sensitive biological endpoint because of the potent sensitizing effect, in the epinephrine-challenged dog model, of many of the halogen containing chemicals and replacement candidates of this program. This study was initiated to evaluate the pharmacokinetic behavior of HCFC-123 in an exposure scenario that mimics the cardiac sensitization test in dogs. Specific emphasis was placed on the measurement of blood and tissue samples following exposure of 1 or 5% HCFC-123 for one to five minutes duration.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 1995
- Accession Number
- ADA367280
Entities
People
- A. Vinegar
- D. E. Dodd
- D. L. Pollard
- J. N. Mcdougal
- R. J. Williams